Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
Acta sci., Biol. sci ; 42: e50517, fev. 2020. ilus, graf
Article in English | LILACS, VETINDEX | ID: biblio-1460908

ABSTRACT

There is a concern about stablishing the clinical risk of drugs used for cancer treatment. In this study, the cytotoxic, clastogenic and genotoxic properties of cis-tetraammine(oxalato)ruthenium(III) dithionite - cis-[Ru(C2O4)(NH3)4]2(S2O6), were evaluated in vitro in human lymphocytes. The mitotic index (MI), chromosomal aberrations (CA) and DNA damage by comet assay were also analyzed. The MTT test revealed that the ruthenium compound showed a slight cytotoxic effect at the highest concentration tested. The IC50 value for the compound after 24 hours of exposure was 185.4 µM. The MI values of human peripheral blood lymphocytes treated with 0.015, 0.15, 1.5 and 150 µM of cis-[Ru(C2O4)(NH3)4]2(S2O6) were 6.1, 3.9, 3.2 and 0.2%, respectively. The lowest concentration, 0.015 µM, did not show any cytotoxic activity. The CA values for the 0.015, 0.15 and 1.5 µM concentrations presented low frequency (1.5, 1.6 and 2.3%, respectively), and did not express clastogenic activity when compared to the negative control, although it was observed clastogenic activity in the highest concentration tested (150 µM). The results obtained by the comet assay suggest that this compound does not present genotoxic activity at lower concentrations. The results show that cis-[Ru(C2O4)(NH3)4]2(S2O6) has no cytotoxic, clastogenic or genotoxic in vitro effects at concentrations less than or equal to 0.015 µM. This information proves as promising in the treatment of cancer and is crucial for future trials.


Subject(s)
Humans , Cytotoxins/analysis , Ruthenium Compounds , Lymphocytes/cytology , Lymphocytes/chemistry , Oxalates , DNA Damage
2.
Acta cir. bras ; 34(12): e201901201, 2019. graf
Article in English | LILACS | ID: biblio-1054690

ABSTRACT

Abstract Purpose To evaluate the effect of Rut-bpy (Cis-[Ru(bpy)2(SO3)(NO)]PF 6), a novel nitric oxide donor, able to modulate the histological changes caused by the NASID (meloxicam). Methods Wistar rats were assigned into three groups (n=6 rats/group): Sham group (saline solution), NSAID group (meloxicam - 15 mg/kg) and Rut-bpy group (100 mg/kg of Rut-bpy associated with 15mg/kg of meloxicam). At the end of experiments, kidneys were removed for histological study, fractal dimension and lacunarity in all animals. Results At the histological examination, all animals (six animals - 100 %) in the NSAID group had membrane thickening and other changes (necrosis, acute tubular congestion and vascular congestion); on the other hand, only one animal (16.6 %) of the Rut-bpy group had congestion. The fractal dimension and lacunarity were greater in the control and Rut-bpy group than in NSAIDs group (p<0.05). Conclusion Rut-bpy may prevent renal histological changes in rats caused by meloxicam.


Subject(s)
Animals , Male , Organometallic Compounds/pharmacology , Ruthenium/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Nitric Oxide Donors/pharmacology , Meloxicam/adverse effects , Kidney Diseases/chemically induced , Kidney Diseases/prevention & control , Random Allocation , Reproducibility of Results , Rats, Wistar , Fractals , Kidney Diseases/pathology
3.
Acta Pharmaceutica Sinica ; (12): 336-344, 2018.
Article in Chinese | WPRIM | ID: wpr-779882

ABSTRACT

Photodynamic therapy (PDT) has emerged as a more effective and promising treatment towards cancer therapy. PDT is a minimally invasive and spatially selective medical technique to destroy cancer cells without drug resistance, which has been increasingly applied in the clinical praxis alongside surgery, chemotherapy and radiotherapy. However, traditional PDTs use a high energy one-photon laser beam, which is far from the efficient optical window of mammalian tissue (650−950 nm). Moreover, it has great limitations in the depth of penetration, and induces the undesired light toxicity. The development of photosensitizers has always been a bottleneck to the effective application of PDT in clinical practice. From the first generation of hematoporphyrin derivatives to the third-generation photosensitizers with tumor targeting ability, they meet the urgent clinical needs to some extent, but they still can not satisfy the requirements of two-photon PDT. Therefore, the development of photosensitizers, which are capable of two-photon activated PDT, has become a promising approach. Among the various two-photon absorption photosensitizers, ruthenium (Ⅱ) polypyridyl complexes have been recognized as excellent candidates due to their attractive photophysical properties. This review is prepared to summarize the recent achievements in the application of ruthenium (Ⅱ) polypyridyl complexes as photosensitizers for two-photon PDT, as well as to provide guidance for the design of two-photon activated photosensitizers in future research.

4.
Chinese Journal of Analytical Chemistry ; (12): 780-786, 2018.
Article in Chinese | WPRIM | ID: wpr-692314

ABSTRACT

The effect of CdS quantum dots (QDs) on the electrochemiluminescence (ECL) signal of Ru(bpy)32+ was studied. It was found that CdS QDs could enhance the anodic ECL of Ru(bpy)32+ by 4 times. The sensitization mechanism was discussed and the influence factors including concentrations of Ru (bpy)32+ and CdS QDs, pH of solution and scan rate on ECL intensity were investigated. On the basis of quenching effect of catechol on the ECL signal of CdS QDs-Ru(bpy)32+,a system for sensitive determination of catechol was established with a detection limit of 5.5 nmol/L (S/N=3). This method was applied to the detection of catechol in tea sample with satisfactory results.

5.
São Paulo; s.n; s.n; 2018. 166 p. graf, tab.
Thesis in Portuguese | LILACS | ID: biblio-1026858

ABSTRACT

Compostos organometálicos do tipo rutênio-areno têm sido estudados no transcurso dos últimos anos em razão do potencial que apresentam para o tratamento de doenças dentre as quais se destaca o câncer. Neste contexto, o presente trabalho teve como principal objetivo o estudo de organometálicos de Ru(II)-p-cimeno contendo como ligantes fármacos anti-inflamatórios não esteroides (FAINEs) ou seus derivados piridinaamida (FAINE-amida). Foram realizadas as sínteses de duas classes de compostos de fórmulas gerais [RuCl(p-cimeno)L] e [RuCl2(p-cimeno)Lam] em que L = ibuprofeno, naproxeno ou indometacina e Lam = derivado amida desses FAINES, respectivamente. A composição e estrutura dos compostos foram elucidadas principalmente com base em análise elementar, espectrometria de massas (ESI-MS), espectroscopia de ressonância magnética nuclear (1H RMN, 13C RMN, HSQC, HMBC) e espectroscopia vibracional ATR/FT-IR. Os dados indicaram que todos os fármacos-ligantes utilizados estabilizam a unidade Ru(II)-areno, sendo que os carboxilatos coordenam-se ao Ru(II) de modo bidentado por ambos os átomos de oxigênio, enquanto que a coordenação dos derivados amida ocorre pelo nitrogênio do anel piridínico. No entanto, em contraste ao comportamento em solventes não-coordenantes como clorofórmio, estudos em solução indicaram que a presença de dimetilsulfóxido promove dissociação do fármaco ligante acompanhada pela coordenação do solvente (gradual, no caso de L, ou imediata total no caso de Lam). Resultados preliminares de estudos de espectroscopia de fluorescência sugerem interação dos compostos de Ru(II)-areno-indometacina com albumina de soro humano (HSA)


Ruthenium-arene organometallics have been investigated in recent years due to the potential for treatment of diseases among which cancer is highlighted. In this context, the main objective of the present work is the study of organometallics of Ru(II)-p-cymene bearing non steroidal anti-inflammatory drugs (NSAIDs) or their pyridine-amide (NSAIDamide) as ligands. Two classes of compounds of general formula [RuCl(p-cymene)L] and [RuCl2(p-cymene)Lam], in which L = ibuprofen, naproxen or indomethacin and Lam = amide derivative of these NSAIDs, respectively have been synthesized. The composition and the structure of these compounds have been elucidated mainly based on elemental analysis, mass spectrometry (ESI-MS), nuclear magnetic resonance spectroscopy (1H RMN, 13C RMN, HSQC, HMBC) and vibrational spectroscopy (ATR/FT-IR). The data indicate that all the used drug-ligands stabilize the Ru(II)-arene framework, being that the carboxylates coordinate Ru(II) in bidentate mode through both oxygen atoms while the coordination of the amide derivatives occurs via nitrogen atom of the pyridine ring. However, in contrast to the behavior in non-coordinating solvents such as chloroform, studies in solution indicate that the presence of dimethylsulfoxide promotes dissociation of the drug ligand accompanied by the coordination of the solvent (gradual, for L, or total immediate for Lam). Preliminary results from fluorescence spectroscopy suggest interaction of the Ru(II)-arene-indomethacin compounds with human serum albumin (HSA)


Subject(s)
Organometallic Compounds/chemical synthesis , Ruthenium/analysis , Mass Spectrometry/instrumentation , Magnetic Resonance Spectroscopy/instrumentation , Anti-Inflammatory Agents
6.
Arq. bras. cardiol ; 109(2): 124-131, Aug. 2017. tab, graf
Article in English | LILACS | ID: biblio-887912

ABSTRACT

Abstract Background: The endothelium is a monolayer of cells that extends on the vascular inner surface, responsible for the modulation of vascular tone. By means of the release of nitric oxide (NO), the endothelium has an important protective function against cardiovascular diseases. Objective: Verify if cis- [Ru(bpy)2(NO2)(NO)](PF6)2 (BPY) improves endothelial function and the sensibility of conductance (aorta) and resistance (coronary) to vascular relaxation induced by BPY. Methods: Normotensive (2K) and hypertensive (2K-1C) Wistar rats were used. For vascular reactivity study, thoracic aortas were isolated, rings with intact endothelium were incubated with: BPY(0.01 to10 µM) and concentration effect curves to acetylcholine were performed. In addition, cumulative concentration curves were performed to BPY (1.0 nM to 0.1 µM) in aortic and coronary rings, with intact and denuded endothelium. Results: In aorta from 2K-1C animals, the treatment with BPY 0.1µM increased the potency of acetylcholine-induced relaxation and it was able to revert the endothelial dysfunction. The presence of the endothelium did not modify the effect of BPY in inducing the relaxation in aortas from 2K and 2K-1C rats. In coronary, the endothelium potentiated the vasodilator effect of BPY in vessels from 2K and 2K-1C rats. Conclusion: Our results suggest that 0.1 µM of BPY is able to normalize the relaxation endothelium dependent in hypertensive rats, and the compound BPY induces relaxation in aortic from normotensive and hypertensive rats with the same potency. The endothelium potentiate the relaxation effect induced by BPY in coronary from normotensive and hypertensive rats, with lower effect on coronary from hypertensive rats.


Resumo Fundamento: O endotélio é uma monocamada de células que se estende sobre a superfície interna vascular, responsável pela modulação do tônus vascular. Por meio da liberação de óxido nítrico (NO), o endotélio tem uma função protetora importante contra doenças cardiovasculares. Objetivo: Verificar se o cis- [Ru (BPY)2 (NO2) (NO)] (PF6) 2 (BPY) melhora a função endotelial e a sensibilidade da condutância (aorta) e da resistência (coronária) ao relaxamento vascular induzido por BPY. Métodos: Foram utilizados ratos Wistar normotensos (2K) e hipertensos (2K-1C). Para o estudo de reatividade vascular, as aortas torácicas foram isoladas, os anéis com endotélio intacto foram incubados com: BPY (0,01 a 10 µM) e se realizaram curvas de efeito de concentração para acetilcolina. Adicionalmente, foram feitas curvas de concentração cumulativas para BPY (1,0 nM a 0,1 µM) nos anéis aórticos e coronários, com endotélio intacto e nu. Resultados: Na aorta de animais 2K-1C, o tratamento com BPY 0,1 µM aumentou a potência do relaxamento induzido pela acetilcolina e foi capaz de reverter a disfunção endotelial. A presença do endotélio não modificou o efeito da BPY na indução do relaxamento em aortas de ratos 2K e 2K-1C. Na coronária, o endotélio potencializou o efeito vasodilatador do BPY em vasos de ratos 2K e 2K-1C. Conclusão: Nossos resultados sugerem que 0,1 µM de BPY é capaz de normalizar o relaxamento dependente do endotélio em ratos hipertensos, e o composto BPY induz relaxamento na aorta de ratos normotensos e hipertensos com a mesma potência. O endotélio potencializa o efeito de relaxamento induzido pela BPY em coronárias de ratos normotensos e hipertensos, com menor efeito em coronárias de ratos hipertensos.

7.
Chinese Pharmacological Bulletin ; (12): 1249-1252,1253, 2016.
Article in Chinese | WPRIM | ID: wpr-604504

ABSTRACT

Aim To analyze the antibiotic activity and mechanism of a polypyridyl ruthenium complex. Meth-ods The antibacterial activity of [ ( Phen ) 2 Ru ( dp-pz) ] ( PF6 ) 2 was determined by MIC and MBC value. Based on a fluorescent activity of this complex, the flu-orescent emission spectra was used to analyze the com-bination of complex to DNA. Then the competition combination was analyzed between complex and Gold View to DNA. Lastly, gel electrophoresis of DNA was applied to detect the combination situation between complex and DNA. Results This kind of polypyridyl ruthenium complex showed a significant antibacterial activity with a minimum antibacterial conentration of 0. 2~0. 4 g · L-1 . That was caused by the combina-tion and distortion of DNA due to the activity of this complex. Conclusion The antibacterial activity and the mechanism of antibacterial activity about [ ( Phen) 2 Ru( dppz) ] ( PF6 ) 2 are confirmed in this re-search, which provides a good foundation for the devel-opment of such class of compound.

8.
Fortaleza; s.n; 2016. 87 p. ilus, tab.
Thesis in Portuguese | LILACS | ID: biblio-971962

ABSTRACT

Os AINEs são um dos principais agentes que contribuem para a patogênese da úlcera gastrintestinal e representam um importante fator etiológico por serem comum enteutilizados na prática clínica. Objetivo: Avaliar o efeito protetor do complexo de rutênio (II)(cis-[RuCl(qui)(bpy)2]PF6), contra a lesão gástrica induzida por na proxeno (NPX) em camundongos. Métodos: Foram utilizados camundongos Swiss (18-22g). Mensuramos os níveis de GMPc incubando amostras de tecidos gástricos com DMSO, com o complexo de Ru (II) e com ODQ, 30 μm de cada composto, por 5 minutos. Os grupos avaliados foram: grupo controle que recebeu CMC, grupo veículo, em que foi administrado NPX (300 mg/kg)e o que recebeu complexo de Ru (II), todos por gavagem. Os animais foram tratados com o complexo de Ru (II), nas doses de 0,3, 3 e 30 mg/kg. Após 30 minutos, seguiu-se com a indução da lesão com NPX. Seguindo o mesmo protocolo,avaliou-se o efeito do composto em estudo e de seus precursores, na dose de 3mg/kg, por gavagem.Verificou-se o efeito do composto na adesão e rolamento leucocitários; seguindo os protocolos descritos, tanto o rolamento quanto a adesão foram avaliados 3h após a indução de gastropatia e de modulação com ODQ (10 mg/kg) por gavagem. Analisou-se o efeito do complexo de Ru (II)em artérias mesentéricas de ratos wistar(200-250g) pré-contraídas com fenilefrina(PHE)(0,3 μM). Simulou-sea ligação entre o composto e a enzima GCs a partir de recursos disponíveis em site que contém banco de dados de proteínas...


NSAIDs contribute to the pathogenesis of gastrointestinal ulcers and represent an important etiologic factor because iscommonly used in clinical practice. Aim:To evaluate the protective effect of the ruthenium complex (II) (cis-[RuCl(qui)(bpy)2]PF6), against the gastric damageinduced by naproxen(NPX)in mice. Methods: Swiss mice were used (18-22g). Measure the GMPc levels incubating samples of gastric tissues with DMSO, with the complex of RU (II) and with ODQ, 30 μm of each compound, for 5 minutes. The groups evaluated were: control group that received CMC, group vehicle, in which was administered NPX (300 mg/kg) and who received complex of RU (II), all by gavage. The animals were treated with the complex of RU (II), in the doses of 0.3, 3 and 30 mg/kg. After 30 minutes, was followed with the induction of the lesion with NPX. Following the same protocol, it was evaluated the effect of the compound and its precursors, in dose of 3mg/kg, by gavage. It was verified theeffect of compound in accession and leukocyte bearing; following the protocols described, both the bearing for accession were evaluated 3h after the induction of gastropathy and modulation with ODQ (10 mg/kg) by gavage. It examined the effect of the complex of RU (II) in mesenteric arteries of Wistar rats (200-250 g) pre-contracted with phenylephrine (PHE) (0.3 μM). Simulated-If the connection between the compound and the enzyme GCs from resources available in the site that contains the database of proteins...


Subject(s)
Humans , Ruthenium , Guanylate Cyclase , Protective Agents
9.
Fortaleza; s.n; 2016. 69 p. ilus.
Thesis in Portuguese | LILACS | ID: biblio-972053

ABSTRACT

Efeitos do nitrosil rutênio na lesão cerebral induzida por isquemia e reperfusão em ratos. MARCIO WILKER SOARES CAMPELO. Pós-Graduação Stricto Sensu do Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal do Ceará (Grau de Mestre em Cirurgia). Novembro, 2009. Orientador: Prof. Dr. Paulo Roberto Leitão de Vasconcelos. Introdução e objetivo: Doadores de NO podem diminuir a lesão neuronal durante a isquemia e reperfusão cerebral (I/R) por aumento do fluxo sanguíneo cerebral. O objetivo deste estudo é avaliar se um novo complexo de nitrosilo complexo de rutênio (Rut-bpy) capaz liberar NO direto na musculatura lisa vascular apresenta algum efeito durante I/R. Método: Foram utilizados 96 ratos machos, da linhagem Wistar, com peso médio de 290.27 g, distribuídos em 2 fases com 8 grupos cada: Fase de isquemia 4 grupos sham (SF, Rut-bpy,L-NAME e L-NAME+Rut-bpy) e 4 grupos isquemia (SF, Rut-bpy,L-NAME e L-NAME+Rut-bpy); da mesma forma foi dividido a fase de reperfusão ( 4 grupos sham e 4 grupos isquemia/reperfusão) com as mesmas drogas teste da fase de isquemia. Foi utilizado um modelo de isquemia cerebral global incompleta, com oclusão da artéria carótida comum bilateral e administração do SF, Rut-bpy e L-NAME via intraperitoneal. No final do experimento os animais foram decapitados e o cérebro fatiado para ser avaliado à área de lesão por histoquímica. Durante todo o experimento a PAM dos animais foi monitorizada...


Effects of nitrosyl ruthenium in injury brain induced by ischemia and reperfusion of rats.MARCIO WILKER SOARES CAMPELO. Stricto SensuPost-graduation. Department of Surgery, Medicine School, Federal University of Ceará (Degree of Master of Surgery). November, 2009. Advisor: Prof. Dr. Paulo Roberto Leitão de Vasconcelos. Background and purpose - Nitric oxide (NO) donors are known to reduce neuronal damage during brain ischemia and reperfusion by increasing the blood flow. Rut-bpy is a novel nitrosyl-ruthenium complex releasing NO directly into the vascular smooth musculature. The objective of the study was to evaluate the effect of Rut-bpy on a rat model of brain ischemia and reperfusion. Methods - Ninety-six male Wistar rats weighing approximately 290g were randomly assigned to 16 groups. Four groups and their respective sham groups were submitted to ischemia (Stage 1), while four groups and their respective sham groups were submitted to ischemia + reperfusion (Stage 2). At each stage of the experiment the groups were treated pairwise with saline solution (SS), Rut-bpy, L-NAME and L-NAME+Rut-bpy, respectively. The study was based on an incomplete global brain ischemia model with occlusion of the common bilateral carotid arteries and intraperitoneal administration of the study drugs. Following the experiment the animals were decapitated and the brain was sectioned for histochemical evaluation of the area of damage. The mean arterial blood pressure (MABP) was monitored throughout the experiment...


Subject(s)
Humans , Brain Ischemia , Oxidative Stress , Nitric Oxide , Ruthenium Compounds
10.
Arq. bras. cardiol ; 104(3): 185-194, 03/2015. tab, graf
Article in English | LILACS | ID: lil-742788

ABSTRACT

Background: Ruthenium (Ru) tetraamines are being increasingly used as nitric oxide (NO) carriers. In this context, pharmacological studies have become highly relevant to better understand the mechanism of action involved. Objective: To evaluate the vascular response of the tetraamines trans-[RuII(NH3)4(Py)(NO)]3+, trans-[RuII(Cl)(NO) (cyclan)](PF6)2, and trans-[RuII(NH3)4(4-acPy)(NO)]3+. Methods: Aortic rings were contracted with noradrenaline (10−6 M). After voltage stabilization, a single concentration (10−6 M) of the compounds was added to the assay medium. The responses were recorded during 120 min. Vascular integrity was assessed functionally using acetylcholine at 10−6 M and sodium nitroprusside at 10−6 M as well as by histological examination. Results: Histological analysis confirmed the presence or absence of endothelial cells in those tissues. All tetraamine complexes altered the contractile response induced by norepinephrine, resulting in increased tone followed by relaxation. In rings with endothelium, the inhibition of endothelial NO caused a reduction of the contractile effect caused by pyridine NO. No significant responses were observed in rings with endothelium after treatment with cyclan NO. In contrast, in rings without endothelium, the inhibition of guanylate cyclase significantly reduced the contractile response caused by the pyridine NO and cyclan NO complexes, and both complexes caused a relaxing effect. Conclusion: The results indicate that the vascular effect of the evaluated complexes involved a decrease in the vascular tone induced by norepinephrine (10−6 M) at the end of the incubation period in aortic rings with and without endothelium, indicating the slow release of NO from these complexes and suggesting that the ligands promoted chemical stability to the molecule. Moreover, we demonstrated that the association of Ru with NO is more stable when the ligands pyridine and cyclan ...


Fundamento: As tetra-aminas de rutênio cada vez mais se destacam como carreadoras da molécula de óxido nítrico. Desse modo, estudos farmacológicos tornam-se altamente relevantes, afim de melhor compreender o mecanismo de ação envolvido. Objetivo: Avaliar a resposta vascular das tetra-aminas trans-[RuII(NH3)4(Py)(NO)]3+, trans-[RuII(Cl)(NO)(Cyclan)](PF6)2 e trans-[RuII(NH3)4(4-acPy)(NO)]3+. Métodos: Anéis de aorta foram pré-contraídos com noradrenalina (10-6M). Após estabilização da tensão, concentração única (10-6M) dos compostos foi adicionada ao banho de incubação. As respostas foram registradas ao longo de 120 minutos. A integridade vascular foi avaliada funcionalmente (acetilcolina 10-6M; nitroprussiato de sódio 10-6M) e histologicamente Resultados: A análise histológica confirmou a presença ou não de células endoteliais nos tecidos analisados. Todos os complexos alteraram a resposta contrátil induzida pela noradrenalina, resultando em aumento de tônus seguido de efeito relaxante. Em anéis com endotélio, a inibição do óxido nítrico endotelial causou redução do efeito contrátil da piridina óxido nítrico. Não foram observadas respostas significativas em anéis com endotélio referente ao composto cyclan óxido nítrico. Por outro lado, em anéis sem endotélio, a inibição da guanilato ciclase reduziu significativamente a resposta contrátil dos complexos piridina óxido nítrico e cyclan óxido nítrico, levando ambos os compostos a um efeito relaxante. Conclusão: Os resultados obtidos demonstram que o efeito vascular dos complexos avaliados apresentaram diminuição no tônus vascular induzido pela noradrenalina (10-6M) ao final do tempo de incubação, em anéis com e sem endotélio, indicando liberação lenta da molécula de óxido nítrico do composto estudado e sugerindo que os ligantes causaram estabilidade química à molécula. Demonstramos que a ligação rutênio óxido nítrico é mais estável quando utilizamos os ligantes piridina e cyclan para a formulação ...


Subject(s)
Animals , Humans , Mice , Apoptosis/physiology , MicroRNAs/physiology , Endothelial Cells/physiology , MicroRNAs/antagonists & inhibitors , MicroRNAs/metabolism , Molecular Targeted Therapy/methods , Neoplasms/physiopathology , Ribonuclease III/deficiency , Ribonuclease III/physiology , Up-Regulation , Vascular Endothelial Growth Factor A/physiology
11.
Chinese Pharmacological Bulletin ; (12): 1592-1597, 2015.
Article in Chinese | WPRIM | ID: wpr-480652

ABSTRACT

Aim To evaluate the antitumor activity of ruthenium polypyridyl complexes and the underlying mechanism. Methods The right complexes 2b were filtered with highest activity and lowest toxicity by MTT assay. The change of cell cycle was detected by flow cytometry . The expression of p53 and p21 was detected by Western blot. The in vivo antitumor activity of 2b was evaluated by the assay of tumor bearing nude mice. Results 2b potentially inhibited proliferation of a variety of hepatoma cell lines, among which Hep 3B cell was the most significant ( IC50 was 12. 1 μmol · L-1 ) . The apoptosis of Hep 3 B cell was induced by 2b, as evidenced by DNA fragmentation, chromatin condensation and appearance of subG1 peak. The ac-tivities of caspase-9 and caspase-3 were activated by 2b. The phosphorylation of p53 was induced by 2b. The expression of p53 and p21 was also up-regulated by 2b. The growth of tumor of nude mice was signifi-cantly inhibited by 2b in vivo experiment. Conclusion 2b has good in vitro and vivo antitumor activities, and it can inhibite growth of Hep 3 B cells by inducing apoptosis.

12.
Chinese Journal of Biochemical Pharmaceutics ; (6): 31-33,37, 2015.
Article in Chinese | WPRIM | ID: wpr-602245

ABSTRACT

Objective To study effect of a novel schiff base ruthenium coordination compound on cell proliferation and apoptosis of gastric cancer SGC-7901 cell.Method Gastric cancer SGC-7901 cell were divided into four groups according to different treatment of novel schiff base ruthenium coordination compound (concentration of 10, 30, 50μmol/L) and blank group with DMSO.Cell proliferation was detected by MTT assay, cell apoptosis and cell cycle were analysed by flow cytometry.ResuIts MTT results showed the inhibitory effect of novel schiff base ruthenium coordination compound on SGC-7901 cell enhanced with the increase of its concentration, and inhibitory rates were higher than that of blank group at 24, 48, 72 h.Flow cytometry results showed the apoptosis rate of novel ruthenium coordination compound groups of 10, 30, 50μmol/L were (17.64 ±1.21)%, (26.47 ± 0.61)%, (55.63 ±1.49)%, respectively, all higher than that of blank group (P<0.05).The cell proportion of G1 phase increased with the increasing of the novel schiff base ruthenium coordination.ConcIusion A novel schiff base ruthenium coordination compound could inhibit the growth of gastric cancer SGC-7901 cells, promote apoptosis and arrest gastric cancer SGC-7901 cells at G1.

13.
Indian J Ophthalmol ; 2014 Sept ; 62 (9): 966-968
Article in English | IMSEAR | ID: sea-155762

ABSTRACT

We report a case of large histopathologically proven melanocytoma of the ciliary body in a 15‑year‑old male, presented with rapid extraocular growth following incisional biopsy with scleral patch graft. We chose brachytherapy with Ruthenium 106 plaque over enucleation as the later was refused by the parents. The initial apical height of the tumor was 14.2 mm on ultrasonography. Two weeks after brachytherapy, the mass regressed to a size of 8.1 mm and 1 year later to 6.7 mm. This is the first case report showing the response of brachytherapy to ciliary body melanocytoma, which results in ocular and visual acuity salvation with considerable decreased in size of the tumor. The authors conclude that brachytherapy is an option in the management of non‑resectable melanocytoma of the ciliary body.

14.
Indian J Ophthalmol ; 2014 Sept ; 62 (9): 966-968
Article in English | IMSEAR | ID: sea-155761

ABSTRACT

We report a case of large histopathologically proven melanocytoma of the ciliary body in a 15‑year‑old male, presented with rapid extraocular growth following incisional biopsy with scleral patch graft. We chose brachytherapy with Ruthenium 106 plaque over enucleation as the later was refused by the parents. The initial apical height of the tumor was 14.2 mm on ultrasonography. Two weeks after brachytherapy, the mass regressed to a size of 8.1 mm and 1 year later to 6.7 mm. This is the first case report showing the response of brachytherapy to ciliary body melanocytoma, which results in ocular and visual acuity salvation with considerable decreased in size of the tumor. The authors conclude that brachytherapy is an option in the management of non‑resectable melanocytoma of the ciliary body.

15.
Salvador; s.n; 2014. 56 p. ilus, tab.
Thesis in Portuguese | LILACS | ID: biblio-1000951

ABSTRACT

A candidíase é uma infecção oportunista provocada por diversas espécies de fungos do gênero Candida, frequentemente encontrados integrando a microbiota, da superfície cutânea, no trato gastrointestinal e cavidades mucosas do ser humano desde o seu nascimento. A incidência das infecções fúngicas sistêmicas têm aumentado consideravelmente nas últimas décadas em função do grande número de pacientes com SIDA, a grande quantidade de transplantes e condições crônicas como o câncer, a terapia prolongada com imunossupressores e o uso de agentes corticosteroides. Além disso, a exposição prolongada aos antifúngicos azólicos promove a seleção de patógenos resistentes. No presente estudo avaliou-se a atividade antifúngica do complexo Rutênio-pirocatecol (RPC) frente a um isolado clinico de Candida tropicalis resistente ao fluconazol. A metodologia empregada para os testes de susceptibilidade foi de acordo com o documento M27-A3 do National Committee for Clinical Laboratory Standards (NCCLS, 2008). Esplenócitos de camundongos Balb/c foram obtidos de forma asséptica para avaliar a citotoxicidade do composto para células de mamíferos. O estresse oxidativo promovido pelo composto foi avaliado através da reação ao ácido tiobarbitúrico (TBARS) e ensaios de fluorescência com a sonda diclorodihidrofluoresceína diacetato (DCFH2DA). O Calcofluor White foi empregado para avaliar a integridade da parede celular. A análise ultraestrutural foi realizada através da microscopia eletrônica de varredura e transmissão. Os resultados encontrados para os testes de atividade antifúngica foram analisados através do teste estatístico ANOVA e pós-teste Dunnett. Os resultados encontrados para os testes de atividade antifúngica do RPC mostraram uma Concentração Inibitória de 50% (IC50) de 20,3 μM, enquanto em esplesnócitos a concentração efetiva de 50% foi de 325 μM mostrando um índice de seletividade igual a 16...


Candidiasis is an opportunistic infection caused by several species of fungi of the genus Candida, often found is the microbiota, on the skin, gastrointestinal tract and mucous cavities of the human beings birth. The incidence of systemic fungal infections have increased considerably in recent decades due to the large number of AIDS patients, the large number of transplants and chronic conditions such as cancer, prolonged therapy promotes the selection of resistant pathogen with immunosuppressant and corticosteroid agents. Also prolonged exposure azole antifungals to make them strong candidates for patients resistance. In the present study we evaluated the antifungal activity of Ruthenium-pyrocatechol complex (RPC) against a clinical isolate of Candida tropicalis resistant to fluconazole. The methodology for susceptibility testing was in accordance with the M27-A3 document of there National Committee for Clinical Laboratory Standards (NCCLS, 2008). Splenocytes from Balb/c mice were obtained aseptically to evaluate the cytotoxicity of the compound to mammalian cells. Oxidative stress caused by the compound was assessed by reaction to thiobarbituric acid (TBARS) and fluorescence assays with the probe diclorodihidrofluoresceína diacetate (DCFH2DA). The Calcofluor White was used to evaluate the integrity of the cell wall. The ultrastructural analysis was performed by scanning and transmission electron microscopy. The results for the antifungal activity tests were analyzed using ANOVA and pos-test Dunnett test statistic. The results for the tests of antifungal activity of the RPC showed a 50% inhibitory concentration (IC50) of 20.3 μM while in splenocytes the 50% effective concentration was 325 μM showing a selectivity index of 16...


Subject(s)
Humans , Antigens/analysis , Antigens/metabolism , Fluconazole , Fluconazole/analysis , Fluconazole/immunology , Fluconazole/chemical synthesis , Sirolimus , Sirolimus/analysis , Sirolimus/adverse effects , Sirolimus/supply & distribution
16.
São Paulo; s.n; s.n; 2014. 127p tab, graf, ilus.
Thesis in Portuguese | LILACS | ID: biblio-847714

ABSTRACT

Complexos de rutênio, em razão da menor toxicidade e por poderem exibir atividade citotóxica ou antimetastática, tem sido considerados como alternativas potencialmente promissoras aos complexos de platina para tratamento de câncer. Nosso grupo de pesquisa tem investigado a interação de íons metálicos com fármacos anti-inflamatórios não esteroides (FAINEs) e já obteve sucesso na preparação de metalofármacos de dirutênio(II,III)-FAINEs, os quais se mostraram promissores com relação à atividade frente a modelos de glioma. Com a finalidade de contribuir para o entendimento das propriedades físico-químicas desses complexos, o presente trabalho teve como principal objetivo analisar propriedades consideradas particularmente essenciais a um potencial candidato a fármaco, tais como, estabilidade no estado sólido, lipofilicidade, solubilidade aquosa e dissolução intrínseca. Um complexo inédito de fórmula [Ru2Cl(feno)4], em que feno = fenoprofenato, foi sintetizado e caracterizado por meio de análise elementar, espectroscopia eletrônica, espectroscopia vibracional, difratometria de raios X, análise térmica e espectrometria de massas. Os complexos já testados anteriormente para atividade biológica, [Ru2Cl(ibp)4], ibp = ibuprofenato, e [Ru2(cet)4Cl], cet = cetoprofenato, foram analisados quanto à estabilidade no estado sólido por meio da determinação isotérmica de variação de massa. As lipofilicidades desses dois complexos, juntamente com a dos fármacos de origem e a do precursor sintético [Ru2(O2CH3)4Cl], foram avaliadas pelo método shake flask, e suas solubilidade aquosas foram investigadas em presença de co-solventes alcoólicos. Investigou-se ainda a velocidade de dissolução intrínseca do [Ru2Cl(ibp)4] que se encontra em estágio avançado de estudos biológicos. Os resultados obtidos trazem novas informações sobre o comportamento térmico dos complexos e sobre suas características biofarmacêutica


Ruthenium complexes, mainly due to the lower toxicity and the cytotoxic and anti-metastatic activities, have been considered as potentially promising alternatives to platinum drugs for cancer treatment. Our research group has investigated the interactions of diruthenium metal cores with anti-inflammatory non-steroidal drugs (NSAIDs) and succeeded in preparing diruthenium(II,III)-NSAIDs metallodrugs which show promising activity against glioma models. With the aim of elucidating the physico-chemical properties of these complexes, the major objective of the present work was to investigate properties which are considered as essential for a potential candidate to drug, e.g., stability in the solid state, lipophilicity, aqueous solubility and intrinsic dissolution. A new complex of formula [Ru2Cl(feno)4], where feno = fenoprofen, was synthesized and characterized by elemental analysis, electronic spectroscopy, vibrational spectroscopy, X-rays difractommetry, thermal analysis and mass spectrometry. The complexes previously tested for biological properties, [Ru2Cl(ibp)4], ibp = ibuprofenate, and [Ru2(cet)4Cl], cet = cetoprofenate, were inv estigated for the stability in the solid state by isothermal thermogravimetry. The lipophilicity of the se complexes, as well as those of the parent drugs and of the precursor [Ru2(O2CH3)4Cl], was evaluated by the shake flask method, and their aqueous solubility in the presence of alcohol co-solvents was investigated. In addition, the intrinsic dissolution rate was determined for [Ru2Cl(ibp)4], which is undergoing advanced biological studies. The results provide important new information on the thermal behavior of the complexes and also on their biopharmaceutical propertie


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Ruthenium/analysis , Solubility , Ruthenium Compounds/analysis , Differential Thermal Analysis/methods , Dissolution/analysis
17.
Chinese Journal of Microsurgery ; (6): 356-359, 2013.
Article in Chinese | WPRIM | ID: wpr-437091

ABSTRACT

Objective To investigate the effects of a novel ruthenium(Ⅱ) polypyridyl complex △-[Ru (phen)2MCMIP]2 + (△-1) on proliferation and apoptosis of human osteosarcoma cell line MG-63 in vitro.Methods Cell counting of kit-8 (CCK-8) assay was used to detect the proliferation of MG-63 cells after 24,48,72h treatment with △-1 under the concentrations of 0.00,12.50,25.00,50.00,100.00,150.00 μmol/L;Changes of apoptosis and cell cycle in MG-63 cells after 24 h treatment of 0.00,25.00,50.00,100.00 μmol/L A-1 were determined and analyzed by flow cytometry (FCM).Results Ruthenium (Ⅱ) polypyridyl complex A-1 could significantly inhibit the growth of MG-63 in a dose and time dependent manner; the IC50 of 24 h,48 h,72 h was 57.80μmol/L,45.27μmol/L,32.51μmol/L respectively; flow cytometry detection showed that A-1 induced 37.10% of apoptosis,while only 1.06% in control group,and arrested cell cycle at G0/G1 phase.Conclusion Ruthenium(Ⅱ) polypyridyl complex A-1 is able to inhibit proliferation and induce apoptosis in MG-63 cells and arrest cell cycle at G0/G1 phase.

18.
Int. braz. j. urol ; 38(5): 687-694, Sept.-Oct. 2012. ilus
Article in English | LILACS | ID: lil-655997

ABSTRACT

PURPOSE: The aim of this study was to evaluate the relaxation in vitro of cavernous smooth muscle induced by a new NO donor of the complex nitrosil-ruthenium, named trans-[Ru(NH3)4(caffeine)(NO)]C13 (Rut-Caf) and sodium nitroprusside (SNP). MATERIALS AND METHODS: The tissues, immersed in isolated bath systems, were pre-contracted with phenilephrine (PE) (1 µM) and then concentration-response curves (10-12 - 10-4 M) were obtained. To clarify the mechanism of action involved, it was added to the baths ODQ (10 µM, 30 µM), oxyhemoglobin (10 µM), L-cysteine (100 µM), hydroxicobalamine (100 µM), glibenclamide, iberotoxin and apamine. Tissue samples were frozen in liquid nitrogen to measure the amount of cGMP and cAMP produced. RESULTS: The substances provoked significant relaxation of the cavernous smooth muscle. Both Rut-Caf and SNP determined dose-dependent relaxation with similar potency (pEC50) and maximum effect (Emax). The substances showed activity through activation of the soluble guanylyl cyclase (sGC), because the relaxations were inhibited by ODQ. Oxyhemoglobin significantly diminished the relaxation effect of the substances. L-cysteine failed to modify the relaxations caused by the agents. Hydroxicobalamine significantly diminished the relaxation effect of Rut-Caf. Glibenclamide significantly increased the efficacy of Rut-Caf (pEC50 4.09 x 7.09). There were no alterations of potency or maximum effect of the substances with the addition of the other ion channel blockers. Rut-Caf induced production of significant amounts of cGMP and cAMP during the relaxation process. CONCLUSIONS: In conclusion, Rut-Caf causes relaxation of smooth muscle of corpus cavernosum by means of activation of sGC with intracellular production of cGMP and cAMP; and also by release of NO in the intracellular environment. Rut-Caf releases the NO free radical and it does not act directly on the potassium ion channels.


Subject(s)
Animals , Male , Rabbits , Muscle Relaxation/physiology , Muscle, Smooth/drug effects , Nitric Oxide Donors/pharmacology , Nitroprusside/pharmacology , Ruthenium Compounds/pharmacology , Cyclic GMP/biosynthesis , Cyclic GMP/chemistry , Cysteine/pharmacology , Guanosine Monophosphate/biosynthesis , Guanosine Monophosphate/chemistry , Muscle, Smooth/physiology , Nitric Oxide Donors/chemistry , Nitroprusside/chemistry , Potassium Channels/chemistry , Ruthenium Compounds/chemistry , Time Factors
19.
Article in English | IMSEAR | ID: sea-163726

ABSTRACT

A new ruthenium (III) Schiff base complexes of the type [RuX2 (PPh3)2(L)] (where X = Cl or Br; L = monobasic bidentate Ligand) have been synthesized. All the complexes were characterized by analytical, IR, electronic and EPR spectral studies. An octahedral geometry has been tentatively proposed to all the new complexes. Further the ligands and complexes were subjected to antimicrobial activity studies. The new complexes have been tested to find out the DNA – binding by electronic spectral studies and anti cancer effect.

20.
Braz. j. med. biol. res ; 44(9): 947-957, Sept. 2011. ilus
Article in English | LILACS | ID: lil-599673

ABSTRACT

During three decades, an enormous number of studies have demonstrated the critical role of nitric oxide (NO) as a second messenger engaged in the activation of many systems including vascular smooth muscle relaxation. The underlying cellular mechanisms involved in vasodilatation are essentially due to soluble guanylyl-cyclase (sGC) modulation in the cytoplasm of vascular smooth cells. sGC activation culminates in cyclic GMP (cGMP) production, which in turn leads to protein kinase G (PKG) activation. NO binds to the sGC heme moiety, thereby activating this enzyme. Activation of the NO-sGC-cGMP-PKG pathway entails Ca2+ signaling reduction and vasodilatation. Endothelium dysfunction leads to decreased production or bioavailability of endogenous NO that could contribute to vascular diseases. Nitrosyl ruthenium complexes have been studied as a new class of NO donors with potential therapeutic use in order to supply the NO deficiency. In this context, this article shall provide a brief review of the effects exerted by the NO that is enzymatically produced via endothelial NO-synthase (eNOS) activation and by the NO released from NO donor compounds in the vascular smooth muscle cells on both conduit and resistance arteries, as well as veins. In addition, the involvement of the nitrite molecule as an endogenous NO reservoir engaged in vasodilatation will be described.


Subject(s)
Animals , Humans , Rats , Endothelial Cells/metabolism , Nitric Oxide Donors/metabolism , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/biosynthesis , Ruthenium Compounds/metabolism , Endothelium, Vascular/metabolism , Hypertension/physiopathology , Muscle, Smooth, Vascular/metabolism , Nitric Oxide/pharmacology , Vasodilation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL